Korean J Hematol 2006; 41(3):
Published online September 30, 2006
https://doi.org/10.5045/kjh.2006.41.3.149
© The Korean Society of Hematology
남은미, 권정미, 이순남, 남승현, 이경은, 문영철, 성주명, 박세훈, 방수미, 조은경, 신동복, 이재훈
이화여자대학교 의과대학 내과학교실,
가천의과학대학교 내과학교실
Background:
Essential thrombocythemia (ET) has a chronic course, but its main clinical features are thrombosis and hemorrhage. We evaluated the clinical features, including the vascular complications in patients with ET, during the disease courses and we determined the predictable risk factors for major vascular complications.
Methods:
From 1991 to 2004, the medical records for 69 patients with ET were retrospectively reviewed for evaluating the clinical features, including the vascular complications, and the predictable risk factors for major vascular complications were analyzed.
Results:
Major vascular thrombotic and hemorrhagic complications were observed in 16 patients (23.2%) and 6 patients (8.7%) at the time of diagnosis, and in 13 (18.8%) and 9 patients (13.0%) during follow-up. The incidence of major vascular thromboses in the older group (age >60 years) was higher than that in the younger group (≤60 years) (34.2% vs 9.7%, respectively, P=0.016) at the time of diagnosis. During follow-up, the major vascular thrombosis risk was increased in patients with a previous thrombosis history (37.5% vs 13.2%, respectively, P=0.029) and in patients with 2 or more combined cardiovascular risk factors (44.4% vs 15.0%, respectively, P=0.035). The probability of 10-year survival in patients with thrombo-hemorrhagic complications during the disease course was lower than that in patients without complication (60.5% vs 93.7%, respectively, P=0.046).
Conclusion:
Advanced age, a previous thrombosis history and the combined cardiovascular risk factors were the risk factors for major vascular thrombosis in patients with ET. Prevention of thrombo-hemorrhagic complications is the most important therapeutic goal. Treatment strategies according to risk factors ought to be prospectively investigated.
Keywords Essential thrombocythemia, Thrombosis, Hemorrhage, Cardiovascular risk factors
Korean J Hematol 2006; 41(3): 149-156
Published online September 30, 2006 https://doi.org/10.5045/kjh.2006.41.3.149
Copyright © The Korean Society of Hematology.
남은미, 권정미, 이순남, 남승현, 이경은, 문영철, 성주명, 박세훈, 방수미, 조은경, 신동복, 이재훈
이화여자대학교 의과대학 내과학교실,
가천의과학대학교 내과학교실
Eun mi Nam, Jung Mi Kwon, Soon Nam Lee, Seung Hyun Nam, Kyoung Eun Lee, Yeung Chul Mun, Chu Myung Seung, Se Hoon Park, Soo Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul,
Gachon University of Medicine and Science Gil Medical Center, Incheon, Korea
Background:
Essential thrombocythemia (ET) has a chronic course, but its main clinical features are thrombosis and hemorrhage. We evaluated the clinical features, including the vascular complications in patients with ET, during the disease courses and we determined the predictable risk factors for major vascular complications.
Methods:
From 1991 to 2004, the medical records for 69 patients with ET were retrospectively reviewed for evaluating the clinical features, including the vascular complications, and the predictable risk factors for major vascular complications were analyzed.
Results:
Major vascular thrombotic and hemorrhagic complications were observed in 16 patients (23.2%) and 6 patients (8.7%) at the time of diagnosis, and in 13 (18.8%) and 9 patients (13.0%) during follow-up. The incidence of major vascular thromboses in the older group (age >60 years) was higher than that in the younger group (≤60 years) (34.2% vs 9.7%, respectively, P=0.016) at the time of diagnosis. During follow-up, the major vascular thrombosis risk was increased in patients with a previous thrombosis history (37.5% vs 13.2%, respectively, P=0.029) and in patients with 2 or more combined cardiovascular risk factors (44.4% vs 15.0%, respectively, P=0.035). The probability of 10-year survival in patients with thrombo-hemorrhagic complications during the disease course was lower than that in patients without complication (60.5% vs 93.7%, respectively, P=0.046).
Conclusion:
Advanced age, a previous thrombosis history and the combined cardiovascular risk factors were the risk factors for major vascular thrombosis in patients with ET. Prevention of thrombo-hemorrhagic complications is the most important therapeutic goal. Treatment strategies according to risk factors ought to be prospectively investigated.
Keywords: Essential thrombocythemia, Thrombosis, Hemorrhage, Cardiovascular risk factors
Sun Joo Cho, Dong Gun Shin, Kyung Hee Lee, Myung Soo Hyun, Ki Young Kwon, Hong Suk Song, Sang Kyun Sohn, Kyu Bo Lee
Korean J Hematol 1999; 34(4): 608-613A-Jin Lee, Sang-Gyung Kim, Jun Yeb Nam, Jaehum Yun, Hun-Mo Ryoo, Sung Hwa Bae
Blood Res 2021; 56(4): 259-265Myung-Won Lee, Jeong Suk Koh, Sora Kang, Hyewon Ryu, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Seon Young Kim, Seong Soo Kim, Deog-Yeon Jo
Blood Res 2023; 58(4): 173-180